市场调查报告书
商品编码
1383370
2030 年数位糖尿病管理市场预测:按产品类型、最终用户和地区分類的全球分析Digital Diabetes Management Market Forecasts to 2030 - Global Analysis By Product, Type, End User and By Geography |
根据 Stratistics MRC 的数据,2023 年全球数位糖尿病管理市场规模将达到 189 亿美元,预计到 2030 年将达到 521 亿美元,预测期内复合年增长率为 15.6%。
糖尿病是一种影响体内血糖水平的慢性疾病。此疾病主要是由于胰臟无法产生胰岛素或稳定体内葡萄糖水平所引起的。糖尿病治疗涉及使用设备和应用来控制体内血糖值。使用这些小工具准确测量糖尿病不仅可以记录和储存资料,还有助于有效治疗患者。
据世界卫生组织称,2018年,糖尿病患者人数大幅增加,从1980年的1.08亿增加到2014年的约4.22亿。全球糖尿病盛行率已从 4.7% 上升至 8.5%。 2016年,约有160万人死于糖尿病。
人工智慧(AI)是一个快速发展的领域,其在糖尿病诊断和治疗中的配合措施彻底改变了治疗这种长期疾病的方式。使用机器学习概念,开发了患有糖尿病和相关併发症可能性的预测模型。临床决策支援对患者和医疗保健提供者都有好处,因为它使患者能够控製糖尿病。这正在刺激市场扩张。
在许多地方,患者仍然更喜欢传统的糖尿病管理方法。由于成本较低且缺乏对连网设备和应用程式的了解,许多患者避开数位平台,转而选择传统的血糖监测。许多国家在糖尿病治疗中缺乏智慧型手机、平板电脑和笔记型电脑的采用也阻碍了最尖端科技的普及。由于知识不足、缺乏合格人员和报销费用低,数位糖尿病照护变得越来越难以使用。
政府旨在提高糖尿病意识和用户友好的胰岛素管理设备介面的计划推动了家庭护理环境中对数位糖尿病给药设备的需求。由于消费者对科技先进产品的意识不断增强,这些小工具在世界各地的使用越来越多。此外,糖尿病盛行率的显着增加和政府宣传宣传活动也可能支持市场扩张。
与已开发国家相比,贫穷国家对技术先进的数位糖尿病管理平台的使用相对较少。这是由于基础设施不足、国家电子医疗政策不明确、需要解决公众对资料隐私和安全的担忧、实现互通性的挑战以及许多因素造成的,包括国内缺乏医疗资讯专业人员。国家和地区缺乏整合策略。这是阻碍市场拓展的因素。
数位糖尿病管理设备市场受到疫情的正面影响。当患有严重肺部感染疾病的患者被送往医院时,控制血糖值变得极为重要。随着药物治疗的给药,患者的血糖值发生了显着变化。此外,疾病管制与预防美国强调了被诊断患有糖尿病和 COVID-19 的患者面临重症患者监护住院的高风险。因此,对管理糖尿病的设备的需求不断增加。
由于与作为显示设备的智慧型设备的兼容性等先进功能,连续血糖监测系统细分市场预计将在预测期内成为最大的细分市场。这是由于技术的持续进步、产品推出的增加、远端监控技术与设备的整合以及社会意识的增强等因素。该技术的使用有助于即时监测患者的血糖值。您还可以整体情况每个人的血糖值。
预计医院领域在预测期内的复合年增长率最高。医院可以利用线上资源和行动应用程式为患者提供糖尿病资讯、自我管理工具和支援。使用这些技术,患者可以更好地了解自己的健康状况、追踪血糖值、管理药物并接受医疗专业人员的指导。
由于先进技术的可用性以及许多数数位血糖病患监测设备最近核准,预计北美将在预测期内保持最大的市场占有率。有利的报销准则和政府支持将进一步促进产业扩张。此外,IT 公司和医疗保健提供者之间的合作也正在推动产业成长。
预计亚太地区在预测期内将维持最高的复合年增长率。该市场预计将因各种因素而发展,例如糖尿病患者数量的增加、医疗保健成本的上升以及该地区市场竞争数量的增加。对糖尿病和其他相关健康问题的健康意识不断增强以及该地区可支配所得的增加预计将成为支持该区域市场扩张的额外因素。
According to Stratistics MRC, the Global Digital Diabetes Management Market is accounted for $18.9 billion in 2023 and is expected to reach $52.1 billion by 2030 growing at a CAGR of 15.6% during the forecast period. Diabetes is a chronic disease that affects the body's glucose levels. This illness is mostly brought on by the pancreas' failure to make insulin or to keep the body's glucose levels stable. Devices and applications are used in diabetes care to control blood glucose levels in the body. Using these gadgets to accurately measure diabetes aids in treating patients effectively as well as recording and retaining data.
According to WHO, in 2018, the number of people suffering with diabetes has significantly risen from 108 million in 1980 to approximately 422 million in 2014. The prevalence of diabetes across the glove has increased from 4.7% to 8.5%. In 2016, around 1.6 million deaths occurred due to diabetes.
Artificial intelligence (AI) is a fast developing field, and its applications in the diagnosis and treatment of diabetes have completely changed how we approach this long-term condition. Predictive models for the likelihood of acquiring diabetes and related complications have been developed using machine learning concepts. Clinical decision support is advantageous to both patients and healthcare providers since people are given more authority to control their diabetes on their own. This is fueling market expansion.
Patients still prefer the old-fashioned ways of managing their diabetes in many places. Many patients steer clear of digital platforms in favor of conventional blood glucose monitoring due to the cheap cost and lack of knowledge about connected devices and applications. The low uptake of smartphones, tablets, and laptops for diabetes treatment in various nations has also hampered the acceptability of cutting-edge technologies. Digital diabetes therapy has been made more difficult to use because to low knowledge, a shortage of qualified workers, and poor reimbursements.
Demand for digital diabetes management devices in homecare settings is being driven by government programs to increase diabetes awareness and user-friendly insulin delivery device interfaces. The increased use of these gadgets around the globe is due to rising consumer awareness of technologically advanced items. Additionally, a significant increase in the prevalence of diabetes and several government awareness campaigns might fuel market expansion.
Comparatively fewer technologically advanced digital diabetes management platforms are used in poorer nations than in industrialized ones. This is attributed to a number of factors, including insufficient infrastructure, hazy national e-health agendas, the need to allay public concerns about data privacy and security, challenges in achieving interoperability, a shortage of qualified health informatics professionals, and a lack of regional integration strategies. This is the element impeding market expansion.
The market for digital diabetes management devices was positively influenced by the epidemic. When patients with serious lung infections were brought to hospitals, controlling blood glucose levels became crucial. The patient's blood glucose levels significantly changed as a result of the disease-treating medications. Additionally, the Centers for Disease Control and Prevention underlined the elevated risk of admission to critical care that persons with diabetes and a COVID-19 diagnosis faced. Devices for managing diabetes become much more necessary as a result.
The continuous blood glucose monitoring system segment is expected to be the largest during the forecast period owing to its advanced features such as compatibility with smart devices that serve as display devices. This is attributed to the factors including on-going technical advancement, an increase in product introductions, more remote monitoring technology integration into devices, and expanding public awareness. The usage of this technology will make it easier to monitor a patient's blood glucose levels in real time. It also provides a complete picture of each person's blood glucose levels.
The hospitals segment is expected to have the highest CAGR during the forecast period. Hospitals can employ online resources or mobile applications that provide patients diabetes information, self-management tools, and support. With the use of these technologies, patients may have a better understanding of their health, track their blood sugar levels, manage their medication, and receive guidance from medical professionals.
North America is projected to hold the largest market share during the forecast period aided by the availability of advanced technologies and the recent approval of many digital blood glucose patient monitoring devices. Favorable reimbursement guidelines and governmental assistance further fuel industry expansion. Additionally, collaborations between IT firms and healthcare providers help the industry grow.
Asia Pacific is projected to hold the highest CAGR over the forecast period. This market is expected to develop as a result of a variety of factors, including an increase in the number of individuals with diabetes, growing healthcare costs, and an increase in the number of market competitors in the area. The expanding health awareness of diabetes and the other linked health issues, as well as the region's rising disposable income, are additional factors projected to support the expansion of this regional market.
Some of the key players in Digital Diabetes Management market include: Sanofi, Medtronic, Abbott Laboratories, Bayer AG, Insulet Corporation, Dexcom, Inc., F. Hoffmann-La Roche Ltd., Johnson and Johnson, B. Braun Melsungen AG, LifeScan, Inc., Terumo corporation., Ascensia Diabetes Care Holdings AG, Novo Nordisk A/S, AGaMatrix , Care Innovaions, LLC, Tandem Diabetes, DarioHealth Corporation and Decide Clinical Software GmbH.
In May 2023, Medtronic plc, a global leader in healthcare technology, announced definitive agreements for the acquisition of EOFlow Co. Ltd., manufacturer of wearable insulin patches to offer the benefits of automated insulin delivery and simplify diabetes treatment.
In April 2023, Glooko, Inc., a prominent software company, inked a Global partnership deal with Hedia, an insulin dosing algorithm company, to offer an interoperable solution that integrates remote patient monitoring, connected care, and digital therapeutic technologies to increase access to people with Type 1 and Type 2 diabetes in need of bolus insulin dosing advice.
In February 2023, Dexcom launched Dexcom G7 CGM device in the US and is planning to launch in Europe and Asia Pacific by first quarter of 2024.